3-Methylimidazo[1,2-a]pyridine-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 3-Methylimidazo[1,2-a]pyridine-2-carboxamide
• 英文别名: 3-methylimidazo[1,2-a]pyridine-2-carboxamide
• 化学式: C₉H₉N₃O
• 分子量: 175.19
• InChiKey: FHEGVWJZAHUBOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• FUSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES
  申请人：BAYER CROPSCIENCE AKTIENGESELLSCHAFT

  公开号：US20180116222A1

  公开（公告）日：2018-05-03

  The invention relates to novel compounds of the formula (I) in which R 1 , R 2 , R 3 , Q and n have the meanings given above, to their use as acaricides and/or insecticides for controlling animal pests and to processes and intermediates for their preparation.

  本发明涉及公式（I）的新化合物，其中R1，R2，R3，Q和n具有上述给定的含义，它们用作杀螨剂和/或杀虫剂以控制动物害虫，并提供它们的制备过程和中间体。
• [EN] AMINO - DIHYDROTHIAZINE AND AMINO - DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE<br/>[FR] COMPOSÉS AMINO-DIHYDROTHIAZINE ET AMINO-DIOXYDO DIHYDROTHIAZINE EN TANT QU'ANTAGONISTES DE BÊTA-SÉCRÉTASE ET PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2014059185A1

  公开（公告）日：2014-04-17

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.
• [EN] FUSED MULTICYCLIC 3-AMINO-5,6-DIHYDRO-2H-1,4-THIAZINE DERIVATIVES AND THEIR USE AS BETA-SECRETASE INHIBITORS<br/>[FR] DÉRIVÉS DE 3-AMINO-5,6-DIHYDRO-2H-1,4-THIAZINE MULTICYCLIQUES CONDENSÉS ET LEUR UTILISATION À TITRE D'INHIBITEURS DE BÊTA-SÉCRÉTASE
  申请人：AMGEN INC

  公开号：WO2014120658A1

  公开（公告）日：2014-08-07

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A5, A6, A8, R1, R2, R3, R7, X, Y, n and o of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.
• [EN] BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA- SECRETASE<br/>[FR] COMPOSÉS DE DIOXYDE D'AMINO-THIAZINE BICYCLIQUES PONTÉS EN TANT QU'INHIBITEURS DE BÊTA-SÉCRÉTASE
  申请人：AMGEN INC

  公开号：WO2015017407A1

  公开（公告）日：2015-02-05

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I, wherein variables A4, A5, A6, A8, R1, R2, R3, R7and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds and the compounds and compositions for treatment of disorders and/ or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions.